top of page

No-Exam Term Life Insurance with Hepatitis B or C: What Accelerated Programs Usually Exclude

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Hepatitis B or C often doesn't fit an instant underwriting track because carriers usually want lab history and treatment details. Options may still exist, but the case often moves to traditional review.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

Hepatitis: Underwriting Needs Lab Context

Treatment history and whether the condition is resolved or controlled

Liver function labs and any fibrosis/cirrhosis history

Time since treatment and follow-up stability

Hepatitis B and C both involve chronic viral infection that can affect liver function over time, but the underwriting analysis for each is distinct and follows different clinical markers. For hepatitis C, the key clinical milestone is sustained virologic response (SVR): a viral load that remains undetectable at 12 weeks after completing antiviral treatment is the clinical definition of a cure. Underwriters are aware of SVR as a concept, but achieving SVR does not automatically trigger an immediate standard offer - carriers typically also want follow-up labs showing ALT and AST normalization, confirming that liver inflammation has resolved along with viral clearance. The time elapsed since SVR and the consistency of normal liver enzymes on subsequent labs both factor into the review.

Hepatitis B underwriting requires distinguishing between two very different serological states. Hepatitis B surface antigen positivity (HBsAg positive) indicates active, ongoing infection - the virus is present and replicating - while hepatitis B surface antibody positivity (anti-HBs positive) indicates immunity from vaccination or prior resolved infection, and underwriters are evaluating active infection status rather than documented immunity. An applicant with anti-HBs positive from vaccination is in a fundamentally different risk category than one with HBsAg positive with active viral replication. Applicants with chronic active hepatitis B on antiviral therapy are evaluated based on viral suppression, treatment duration and adherence, and liver function markers - all of which must be documented through lab results rather than self-report alone.

Liver fibrosis staging is increasingly important in hepatitis underwriting as non-invasive assessment tools have become more common in clinical practice. Fibroscan (transient elastography), the APRI score (AST-to-platelet ratio index), and the FIB-4 index are non-invasive fibrosis markers that estimate liver scarring without a biopsy, and carriers may ask whether staging has been done and what the result was because fibrosis stage dramatically changes the underwriting outcome. F0 to F2 (no fibrosis to moderate fibrosis) is evaluated very differently than F3 (significant fibrosis) or F4 (cirrhosis), which represents end-stage liver disease associated with meaningfully higher mortality risk. An applicant who has undergone non-invasive fibrosis assessment and has documented F0 or F1 results is in a significantly stronger documentation position than one whose records contain no fibrosis assessment at all.

Hepatocellular carcinoma (HCC) surveillance history is relevant underwriting information for applicants with a history of cirrhosis or significant fibrosis. Clinical guidelines recommend ultrasound screening every six months for cirrhotic patients because cirrhosis carries an elevated risk of developing HCC. If an applicant is actively enrolled in HCC surveillance, that tells the underwriter two things simultaneously: the applicant has documented risk factors for liver cancer, and the treating physician considers that risk significant enough to warrant structured monitoring. Current participation in an HCC surveillance program is not disqualifying on its own, but it places the case in a category where the underwriter will examine liver function labs, fibrosis stage, and viral control closely before making a decision.

The reason instant and no-exam programs consistently screen out hepatitis histories is that the relevant data - viral load trends, liver enzyme series, fibrosis staging, HCC surveillance status - exists in lab results and specialist records, not in a yes/no health question. An accelerated program cannot evaluate that data in real time, so it applies a conservative filter. Traditional underwriting, where the carrier can request and review those records, is the realistic path to coverage for most applicants with hepatitis history. Preparing a concise summary of diagnosis type, treatment timeline, most recent labs, and follow-up frequency gives the underwriting conversation a factual foundation from the start rather than requiring multiple documentation requests before an offer can be made.

For the main no-exam term life overview and underwriting basics, see: https://www.careproinsurance.com/instant-term-life-insurance

Informational purposes only; consult a licensed professional for legal, tax, or medical questions. Quote-stage pricing gives a directional estimate that underwriting may revise.

Frequently Asked Questions

Can I get no-exam term life insurance with hepatitis C?

Sometimes, but many accelerated/no-exam programs are restrictive and may require a fuller review. Options depend on treatment history, labs, and overall profile.

Does cured hepatitis C change underwriting?

It can. Underwriters may consider time since treatment and follow-up labs. Carrier guidelines vary, and underwriting may still request documentation.

What do carriers look at for hepatitis B or C?

Common focus areas include treatment history, liver function labs, any fibrosis/cirrhosis findings, and stability over time with medical follow-up.

Will I need a medical exam with hepatitis history?

Not always, but additional documentation is common. Requirements depend on the carrier, coverage amount, and specifics of your history.

Why do instant programs often exclude hepatitis?

Because accelerated programs rely on fast screening rules and may not be able to evaluate lab trends and long-term stability quickly. Exact filters vary by carrier.

What is SVR and does achieving it mean I qualify for standard rates?

SVR, or sustained virologic response, is the clinical benchmark for hepatitis C cure - undetectable viral load at 12 weeks post-treatment. Achieving SVR is favorable for underwriting, but it does not automatically produce a standard rate class offer. Carriers also want confirmation of normalized liver enzymes (ALT, AST) and sufficient time post-treatment with clean follow-up labs before placing the case at standard rates. Guidelines and waiting periods vary by carrier.

How do carriers evaluate hepatitis B in someone who is on antiviral treatment?

For applicants with chronic hepatitis B on antiviral therapy, underwriters typically focus on viral suppression (whether the viral load is undetectable or low on treatment), treatment duration and adherence, liver function labs (ALT, AST), and whether fibrosis staging has been done. Stable viral suppression with normal liver enzymes over an extended period is more favorable than recent treatment initiation or inconsistent lab results.

Will a history of hepatitis affect the term length I can get approved for?

In some cases, yes. When a carrier approves a case with hepatitis history, it may offer coverage with a rating (table rating or flat extra) or may limit the available term lengths depending on the severity of liver involvement. F3 or F4 fibrosis, for example, may restrict options significantly regardless of viral status. The specific term length available depends on the carrier's guidelines and the individual health profile.

Get Covered With The Right Plan

Explain why hepatitis B/C often triggers accelerated-program screens, and what underwriters evaluate (treatment, viral load, liver function) in a fuller review.

Compare term life options

bottom of page